News & Updates
Showing Multidisciplinary articles
Showing

STAMP inhibitor bests all TKIs in pivotal head-to-head CML study
In the phase III ASC4FIRST study, asciminib – the first BCR::ABL1 inhibitor to Specifically Target the ABL Myristoyl Pocket (STAMP) – trumped all investigator-selected tyrosine kinase inhibitors (IS-TKIs; imatinib, nilotinib, dasatinib, and bosutinib) for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP).

Empagliflozin reduces hepatic fat content in nondiabetic MASLD patients
Empagliflozin significantly reduces hepatic fat content vs placebo in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) without diabetes, researchers from the University of Hong Kong have reported.

Apremilast delivers favourable outcomes for patients with early oligoarticular PsA
In the treatment of patients with early oligoarticular psoriatic arthritis (PsA), the use of apremilast yields substantial improvements in both clinical and patient-reported outcomes, as shown in the results of the phase IV FOREMOST study.






